Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal
antibody for patients with recurrent inoperable stage III or stage IV melanoma.